Dafalgan 500 mg tablets

Dafalgan is a well-known Swiss pharmaceutical brand specializing in paracetamol-based pain relief. The product shown, identified by its dosage and the Swissmedic logo, is a staple in Swiss healthcare for treating fever and various types of pain.

Originally developed by the Swiss pharmaceutical company Bristol-Myers Squibb SA (Switzerland), the brand has maintained a strong manufacturing presence in Switzerland for the local market. Today, the brand is part of the UPSA group.

In 2019, the Japanese pharmaceutical giant Taisho Pharmaceutical completed the acquisition of UPSA from Bristol-Myers Squibb. This move established Taisho as the ultimate owner, integrating European pharmaceutical expertise with global Japanese operations to ensure the continued distribution of this essential medication.